Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000017.xml
Download PDF
CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes 2025; 133(03): 120-132
DOI: 10.1055/a-2498-6826
DOI: 10.1055/a-2498-6826
Review
Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?
Authors
Abstract
Objective
Recent studies have suggested that improved glycemic control in patients with diabetes may cause acute Charcot foot. To conduct a narrative review of studies investigating whether improved glycemic control in patients with diabetes causes acute Charcot foot.
Method
Publications found by searching PubMed, EMBASE, and Cochrane Library as well as reference lists of identified publications were reviewed.
Results
Very few publications were found, primarily consisting of case reports and case studies without control groups, documenting instances where cases of acute Charcot foot had been preceded by improved glycemic control. Recent large multicenter randomized placebo-controlled clinical trials of anti-hyperglycemic agents in patients with diabetes, where significant improvement of glycemic control occurred, have not reported incidences of acute Charcot foot.
Conclusion
There is so far no solid evidence to suggest that improvement of glycemic control in patients with diabetes causes acute Charcot foot.
Publication History
Received: 06 August 2024
Accepted after revision: 02 December 2024
Article published online:
22 January 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Rogers LC, Frykberg RG, Armstrong DG. et al. The Charcot foot in diabetes. Diabetes Care 2011; 34: 2123-2129
- 2 Svendsen OL, Rabe OC, Winther-Jensen M. et al. How common is the rare Charcot foot in patients with diabetes. Diabetes Care 2021; 44: e62-e63
- 3 Jansen RB, Jørgensen B, Holstein PE. et al. Mortality and complications after treatment of acute diabetic Charcot foot. J Diabetes Complications 2018; 32: 1141-1147
- 4 Jansen RB, Svendsen OL. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot. J Diabetes Complications 2018; 32: 708-712
- 5 Jansen RB, Christensen TM, Bülow J. et al. Bone mineral density and markers of bone turnover and inflammation in diabetes patients with or without a Charcot foot: An 8.5-year prospective case-control study. J Diabetes Complications 2018; 32: 164-170
- 6 Dardari D. Trends in the pathophysiology of Charcot neuroarthropathy. Trends Endocrinol Metab 2023; 34: 61-62
- 7 Poonoosamy J, Lopes P, Huret P. et al. Impact of intensive glycemic treatment on diabetes complications – a systematic review. Pharmaceutics 2023; 15: 1791
- 8 Dardari D, Ha Van G, M’Bemba J. et al. Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot’s acute neuroarthropathy. PLoS One 2020; 15: e0233168
- 9 Dardari D, Schuldiner S, Julien CA. et al. Trends in the relation between hyperglycemia correction and active Charcot neuroarthropathy: Results from the EPICHAR study. BMJ Open Diab Res Care 2022; 10: e002380
- 10 Dardari D, Penfornis A, Hartemann A. The onset of acute Charcot neuroarthropathy during pregnancy in type 1 diabetes. Endocrinol Diabetes Metab Case Rep 2020; 2020: 20-0002
- 11 Dardari D, Penfornis A, Amadou C. et al. Multifocal (tarsus and knee) activation of neuroarthropathy following rapid glycaemic correction. J Diabetes Complications 2019; 33: 107348
- 12 Huret P, Lopes P, Dardari R. et al. Rapid correction of Hyperglycemia: A necessity but at what price? A brief report of a patient living with type 1 diabetes. World J Diabetes 2023; 14: 1710-1716
- 13 Murchison R, Gooday C, Dhatariya K. The development of a Charcot foot after significant weight loss in people with diabetes: Three cautionary tales. J Am Podiatr Med Assoc 2014; 104: 522-555
- 14 Valabhji J. Immunosuppression therapy posttransplantation can be associated with a different clinical phenotype for diabetic Charcot foot neuroarthropathy. Diabetes Care 2011; 34: e135
- 15 Vecchio JJ, Raimondi N, Rivarola H. et al. Charcot neuroarthropathy in simultaneous kidney-pancreas transplantation: Report of two cases. Diabet Foot Ankle 2013; 4: 1-5
- 16 Matricali G, Bammens B, Kuypers D. et al. High rate of Charcot foot Attacks early after simultaneous pancreas-kidney transplantation. Transplantation 2007; 83: 245-246
- 17 Garcia Barrado F, Kuypers DR, Matricali GA. Charcot neuropathy after simultaneous pancreas-kidney transplantation: Risk factors, prevalence, and outcome. Clin Transplant 2015; 29: 712-719
- 18 Rangel ÉB, Sá JR, Gomes SA. et al. Charcot neuroarthropathy after simultaneous pancreas-kidney transplant. Transplantation 2012; 94: 642-645
- 19 Anthony ML, Cravey KS, Atway SA. Development of Charcot neuroarthropathy in diabetic patients who received kidney or kidney-pancreas transplants. J Foot Ankle Surgery 2019; 58: 475-479
- 20 Søe K, Delaissé JM. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res 2010; 25: 2184-2192
- 21 Liu T, Wang Y, Quian B. et al. Potential metabolic pathways involved in osteoporosis and evaluation of fracture risk in individuals with diabetes. BioMed Res Int 2024; 2024: 6640796
- 22 Saito M, Kida Y, Kato S. et al. Diabetes, collagen and bone quality. Curr Osteoporos Rep 2014; 12: 181-188
- 23 Das L, Bhansali A, Prakash M. et al. Effect of methylprednisolone or zoledronic acid on resolution of active Charcot neuroarthropathy in Diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Care 2019; 42: e185-e186
- 24 Petrova NL, Dew TK, Musto RL. et al. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy. Diabet Med 2015; 32: 267-273
- 25 Xiang GD, Sun HL, Zhao LS. et al. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Zhonghua Yi Xue Za Zhi 2007; 87: 1234-1237
- 26 Rasmussen LM, Tarnow L, Hansen TK. et al. Plasma osteoprotegerin levels are associated with glycemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75-81
- 27 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637
- 28 Avignon A, Sultan A, Piot C. et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care 2005; 28: 2176-2180
- 29 Anand DV, Lahiri A, Lim E. et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857
- 30 Zobel EH, von Scholten BJ, Lajer M. et al. High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. J Diabetes Complications 2016; 30: 1603-1608
- 31 Knudsen ST, Foss CH, Poulsen PL. et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149: 39-42
- 32 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
- 33 Dhatariya K, Bain SC, Buse JB. et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for Cardiovascular events: Results from the LEADER trial. Diabetes Care 2018; 41: 2229-2235
- 34 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
- 35 Rosenstock J, Wysham C, Frías JP. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet 2021; 398: 143-155
- 36 Rosenstock J, Juan Frias J, Jastreboff AM. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402: 529-544
- 37 Goldney J, Sargeant JA, Davies MJ. Incretins and microvascular complications of diabetes: Neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia 2023; 66: 1832-1845
- 38 Kandeel M. The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2I) on diabetes-associated neuropathy: A systemic review and meta-analysis. Front Pharmacol 2022; 13: 926717
- 39 Rosenstock J, Stephen C, Bain SC. et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 2023; 389: 297-308
- 40 Gibbons CH. Treatment-induced neuropathy of diabetes. Curr Diab Rep. 2017 127.
- 41 Bain SC, Klufas MA, Ho A. et al. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab 2019; 2154-2466
- 42 American Diabetes Association Professional Practice Committee. Retinopathy, neuropathy, and foot care: Standards for care in diabetes – 2024. Diabetes Care 2024; 47: S231-S243